TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03632486

Intervention type: OTHER
Intervention: Bedside Ultrasound
Description: Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~* Lung ultrasound to assess for pleural effusions and sonographic b lines.
Study: NCT01323855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
Study: NCT03697135

Intervention type: BEHAVIORAL
Intervention: Respondent Driven Sampling
Description: Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C

Intervention type: BEHAVIORAL
Intervention: Respondent Driven Sampling
Description: Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C

Intervention type: BEHAVIORAL
Intervention: Respondent Driven Sampling
Description: Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
Study: NCT03970980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fraction of inspired oxygen (FIO2)
Description: Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fraction of inspired oxygen (FIO2)
Description: Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
Study: NCT02188901

Intervention type: OTHER
Group type: OTHER
Intervention: Sonazoid-enhanced ultrasonography
Description: Sonazoid (perflubutane) \[GE healthcare\]
Study: NCT02691871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg/d) + Docetaxel (60 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/d) + Docetaxel (60 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib (750 mg/d) + Docetaxel (60 mg/m2)
Study: NCT00830908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HairMax LaserComb
Description: LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
Study: NCT04727021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg tablet rivaroxaban
Description: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban, granules for oral suspension
Description: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.
Study: NCT02870023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study: NCT04135105

Intervention type: OTHER
Intervention: Normal hearing group
Description: Observational
Study: NCT03911687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONCERN CDS system notification
Description: The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months
Study: NCT01414920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875 and Sitagliptin
Description: TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875 and Sitagliptin
Description: TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
Study: NCT03489746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICS withdrawal protocol
Description: A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Normal clinically indicated inhaled therapy
Study: NCT03498053

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro
Description: Participants smoke Marlboro during the first experimental day, ad libitum.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro Prime
Description: Participants smoke Marlboro Prime during the second experimental day, ad libitum.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marlboro Prime (ventilation holes taped)
Description: Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
Study: NCT01129193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Studies
Description: Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Inventory
Description: Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic studies
Description: Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-42
Description: Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-42
Description: Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
Study: NCT03198689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
Study: NCT01813994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm1: Statin
Description: Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Study: NCT02862509

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline nasal instillation
Study: NCT01499407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearWay RX catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearWay RX catheter
Study: NCT01499407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Study: NCT04323592

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 \> 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 \> 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.

Intervention type: OTHER
Intervention: standard care
Description: usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins

Intervention type: OTHER
Intervention: standard care
Description: usual standard of care:~* oxygen therapy (regular or high-flow) and monitoring~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* ECMO when needed and available~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins
Study: NCT04236960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group ACYW135 Conjugate Vaccine
Description: 1 dose in Stage 1 (2\~55 yrs), 2 doses in Stage 2 (7\~23 mos), and 3 doses in Stage 3 (2\&3 mos)
Study: NCT03243630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV nicotine
Description: Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
Study: NCT03625674

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: explanation when prescribing psychoactive medicine
Description: explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
Study: NCT03243630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV nicotine
Description: Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV nicotine
Description: Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Menthol flavor
Description: American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
Study: NCT03625674

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: explanation when prescribing psychoactive medicine
Description: explanation of the pathogenesis of FD and the mechanism of psychoactive medicine

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: explanation when prescribing psychoactive medicine
Description: explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
Study: NCT02868827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk (Nestle)
Description: 45 ml of Nestle milk will given to patients assigned as placebo
Study: NCT03141996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration to upper posterior neck muscles
Description: Vibration to upper posterior neck muscles using a vibrational tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment
Study: NCT00543244

Intervention type: DRUG
Intervention: Pegylated interferon alfa and ribavirin
Description: Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: \< 75 kg 1000 mg/day, \>=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)
Study: NCT05094973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere Motion Appliance®
Description: To analyze the distalization or distal tooth displacement and derotation angle produced by Carriere Motion Appliance® in a period of 4 months.
Study: NCT00345332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected
Study: NCT00911885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
Study: NCT03207165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Patients will be initiated on Milrinone at 0.125 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[0.250, 0.375, 0.5 and \>0.5 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Patients will be initiated on Dobutamine at 2.5 mcg/kg/min \[stage 1\] and will be titrated according to a blinded protocol from stages 2 to 5 \[5.0, 7.5, 10 and \>10 ug/kg/min\]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be \[increased/decreased/maintained\] at stage \[1-5\]' so as to ensure that treating physicians remain blinded to the allocated drug.
Study: NCT02866955

Intervention type: DRUG
Group type: OTHER
Intervention: Estramustine
Description: 140mg/4 caps/day

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: 20mg/day
Study: NCT02942940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile app
Description: The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional in-person
Description: Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
Study: NCT03661879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1706
Description: Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC9204-1706)
Description: Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
Study: NCT02551796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lenticule extraction
Description: Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser in situ keratomileusis
Description: During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
Study: NCT03243630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol flavor
Description: American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol flavor
Description: American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: green apple
Description: green apple will be added to the menthol flavor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green apple
Description: green apple will be added to the menthol flavor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green apple
Description: green apple will be added to the menthol flavor
Study: NCT00562341

Intervention type: OTHER
Intervention: Bariatric Surgery
Description: one time lapb-band gastric bypass surgery
Study: NCT03243630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: green apple and menthol
Description: menthol and green apple will be the active intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green apple and menthol
Description: menthol and green apple will be the active intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green apple and menthol
Description: menthol and green apple will be the active intervention
Study: NCT03626649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiamondTemp Cardiac Ablation System
Description: The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~* DiamondTemp Ablation Catheter~  o Unidirectional and Bidirectional models~* DiamondTemp Catheter-to RFG Cable~* DiamondTemp GenConnect Cable~* DiamondTemp FASTR Generator with Footswitch~* DiamondTemp Irrigation Pump~* DiamondTemp Irrigation Tubing Set
Study: NCT01424293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 1ml of intravenous ICG and imaging transanally using the Spyscope system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The SPY® Intraoperative Imaging System